Segments (Tables)

3 Months Ended

Mar. 31, 2026

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM reflecting the changes made by the company's re-priortized pipeline, as computed under U.S. GAAP, to the Company’s total net loss in the statements of operations (in thousands).


	Three Months Ended March 31,
	2026		2025
Operating expenses:
Program expense including clinical trial and third party contracting costs	$	5,585	$	1,436
Bexotegrast - clinical trial and third party contracting costs	(777)		21,589
Employee-related expenses - research and development (excluding stock-based compensation)	3,537		10,486
General and administrative costs (excluding stock-based compensation)	5,661		10,289
Other segment items	7,766		15,135
Segment loss	21,772		58,935
Reconciliation of segment loss
Interest and other (income) expense, net	(1,732)		(3,568)
Interest expense	—		799
Net loss	$	20,040	$	56,166